Gilead Sciences Announces Fourth Quarter and Full Year 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Gilead Sciences (GILD) Tops Q4 EPS by 19c, Offers Guidance
February 11, 2025 4:04 PM ESTGilead Sciences (NASDAQ: GILD) reported Q4 EPS of $1.90, $0.19 better than the analyst estimate of $1.71. Revenue for the quarter came in at $7.6 billion versus the consensus estimate of $7.16 billion.
GUIDANCE:
Gilead Sciences sees FY2025 EPS of $7.70-$8.10, versus the consensus of... More
